PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain  by Lambert, Jeremy M.R. et al.
Cancer Cell
ArticlePRIMA-1 Reactivates Mutant p53
by Covalent Binding to the Core Domain
Jeremy M.R. Lambert,1,2 Petr Gorzov,1 Dimitry B. Veprintsev,3 Maja So¨derqvist,1 Dan Segerba¨ck,4 Jan Bergman,4
Alan R. Fersht,3 Pierre Hainaut,2 Klas G. Wiman,1,* and Vladimir J.N. Bykov1
1Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, SE-171 76 Stockholm, Sweden
2International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
3Centre for Protein Engineering, Medical Research Council, Cambridge CB2 2QH, UK
4Department of Biosciences and Nutrition, Karolinska Institutet, Novum, SE-141 57, Huddinge, Sweden
*Correspondence: klas.wiman@ki.se
DOI 10.1016/j.ccr.2009.03.003
SUMMARY
Restoration of wild-type p53 expression triggers cell death and eliminates tumors in vivo. The identification of
mutant p53-reactivating small molecules such as PRIMA-1 opens possibilities for the development of more
efficient anticancer drugs. Although the biological effects of PRIMA-1 are well demonstrated, little is known
about its molecular mechanism of action. We show here that PRIMA-1 is converted to compounds that form
adducts with thiols in mutant p53. Covalent modification of mutant p53 per se is sufficient to induce
apoptosis in tumor cells. These findings might facilitate the design of more potent and specific mutant
p53-targeting anticancer drugs.INTRODUCTION
The transcription factor p53 is activated in response to cellular
stress (Lane, 2004; Vousden and Lu, 2002) leading to cell cycle
arrest, senescence, and/or apoptosis. p53 mutation occurs
frequently in human tumors (Hollstein et al., 1991; Olivier et al.,
2002) and plays a critical role in tumor evolution by allowing
evasion from p53-dependent arrest or cell death. Mutation of
p53 might also increase resistance to chemotherapy (Olivier
et al., 2006). These observations, and the finding that mutant p53
is often expressed at high levels, make mutant p53 an important
target for cancer therapy. Screening studies have identified small
molecules, includingCP-31398,WR-1065,PRIMA-1,andMIRA-1,
that reactivate mutant p53 (Bykov et al., 2002a, 2002b, 2005a;
Foster et al., 1999). PRIMA-1 and its methylated version
PRIMA-1MET induce several p53 target genes and mutant p53-
dependent apoptosis in human tumor cells (Bykov et al., 2002b,
2005a, 2005b; North et al., 2002). Systemic administration of
PRIMA-1 or PRIMA-1MET inhibits human xenograft tumor growth
in mice (Bykov et al., 2002b; Foster et al., 1999). PRIMA-1 also
restores mutant p53-mediated transcription-independent376 Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc.apoptosis (Chipuk et al., 2003). Moreover, PRIMA-1MET synergizes
withchemotherapeuticdrugs to induce tumorcell apoptosis (Bykov
et al., 2005b; Nahi et al., 2004, 2006; Rehman et al., 2005). Never-
theless, the exact molecular mechanism by which PRIMA-1 and
PRIMA-1MET and other mutant p53-targeting compounds restore
wild-type function tomutant p53 and/or affect other cellular targets
has remained unknown. A better understanding of the molecular
mechanisms should facilitate rational drug design of more potent
and specific molecular scaffolds for mutant p53 reactivation.
Here we have investigated the chemical properties of
PRIMA-1 and PRIMA-1MET and their potential binding to mutant
p53. We propose that covalent modification of thiol groups in the
mutant p53 core domain is responsible for the observed mutant
p53 reactivation by PRIMA-1 and PRIMA-1MET.
RESULTS
Decomposition of PRIMA-1 and PRIMA-1MET and Its Role
for Biological Activity
To examine potential degradation of PRIMA-1 and the analog
PRIMA-1MET, we incubated each compound at 37C at pH 7.4SIGNIFICANCE
Given the frequent mutations of p53 in almost all types of human tumors, mutant p53-targeting drugs should have a wide
clinical applicability. Moreover, because mutant p53-carrying tumors are usually more resistant to currently used chemo-
therapy, there is an urgent need for more effective treatment of such tumors. We demonstrate that modification of thiol
groups in mutant p53 by PRIMA-1 conversion products is sufficient to restore its tumor suppressor activity. This might
open possibilities for the design of more potent mutant p53-specific compounds based on the same or a similar molecular
mechanism, and eventually the development of efficient anticancer drugs.
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Figure 1. Chemical Stability of PRIMA-1 and PRIMA-1MET In Vitro and in Living Cells
(A) HPLC profiles of untreated (upper panel) and preheated (lower panel) PRIMA-1 and PRIMA-1MET. Preheating was performed in PBS for 24 hr at 37C or 20min
at 90C. The major decomposition products of PRIMA-1 and PRIMA-1MET have identical retention times on HPLC and coeluted with each other.
(B) Structural formulas of the identified decomposition products of PRIMA-1 and PRIMA-1MET.
(C) Chromatogram of lysate from cells treated with 50 mM [14C]-PRIMA-1 for 24 hr.
(D) Chromatograms of serum and urine from [14C]-PRIMA-1-treated mice at 1 and 24 hr after intravenous injection. The estimation of the retention time of
PRIMA-1 on the chromatograms is based on coelution with the internal standard of cold PRIMA-1 spiked with actual samples and traced by UV-detector.
(E) Distribution of [14C]-PRIMA-1 in organs in vivo at 1, 2, and 24 hr after intravenous injection of radiolabeled PRIMA-1.in phosphate-buffered saline (PBS) for various periods and
analyzed samples by high-pressure liquid chromatography
(HPLC). Incubation resulted in a time-dependent conversion of
the parental compounds and the elution on HPLC yielded two
major peaks at 15.0 and 24.0 min (Figure 1A). Half of the starting
material of PRIMA-1 and PRIMA-1MET was converted to other
products after 41.4 and 32.6 hr, respectively. Incubation at
90C for 20 min resulted in an identical pattern of degradation
as that obtained by incubation at 37C for 3 days (Figure 1A
and data not shown). Analysis of the collected peaks by mass
spectrometry (MS) and 1H nuclear magnetic resonance (NMR)
showed that the fraction eluted at 15 min contains a mixture of
three compounds with molecular masses of 137 and 155 Da
(Figure 1B). The former is denoted methylene quinuclidinone
(MQ). Other detected products could not be identified.To determine if decomposition of PRIMA-1 occurs in living
cells, we treated H1299-His175 cells with [14C]-labeled PRIMA-1
for 24 hr and analyzed the cell lysates by HPLC. We observed
significant decomposition after 4 hr, and only a minor portion
of the starting material could be detected in cells after 24 hr
(Figure 1C). We conclude that conversion of PRIMA-1 occurs
even more efficiently in living cells than in vitro. Furthermore,
we treated Balb/c mice with [14C]-PRIMA-1 by intravenous injec-
tion and analyzed serum and urine by HPLC. In agreement with
our data from experiments in cultured cells, we detected nearly
complete decomposition of PRIMA-1 already at 1 hr after treat-
ment (Figure 1D). The emerged radioactive products in both
serum and urine eluted faster than the PRIMA-1 decomposition
products shown in Figure 1A. These metabolites can be ex-
pected to be short-lived in complex environments such asCancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc. 377
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ucts of their reaction with other molecules carrying thiol groups,
rather than the decomposition products themselves in their free
form, are detected in vivo (Figure 1D). Also, we examined the
distribution of PRIMA-1 in vivo in various organs (Figure 1E).
Only a small portion of the radioactivity was detected in the brain,
suggesting that PRIMA does not efficiently penetrate the blood-
brain barrier. The highest amount of radioactivity was detected in
kidneys, indicating that PRIMA-1 is excreted from the body via
the urine and that the excretion is very rapid. Only around 3%
of the radioactivity remained in serum after 24 hr as compared
with 1 hr after the injection, and more than 99% of the radioac-
tivity was found in urine as compared to serum at this time point.
The putative decomposition of PRIMA-1 and PRIMA-1MET is
shown in Figure 2A. Conversion according to this scheme should
generate formaldehyde. Using the Purpald reagent, we con-
firmed that both PRIMA-1 and PRIMA-1MET released formalde-
hyde (datanot shown).ExposureofH1299-His175cells toa range
of formaldehyde concentrations up to 50 mM did not induce any
growth suppression (data not shown). Thus, formaldehyde is
unlikely to be responsible for PRIMA-1-induced cell death.
If conversion of PRIMA-1/PRIMA-1MET is required for its bio-
logical effects, PRIMA-1 analogs that cannot be decomposed
as shown in Figure 2A should be inactive. To test this, we synthe-
sized a molecule termed PRIMA-D that closely resembles
PRIMA-1 but cannot be converted to MQ (Figure 2C). PRIMA-D
was completely inactive with respect to induction of apoptosis in
H1299-His175 cells at concentrations up to 100 mM (data not
shown). No decomposition of PRIMA-D was detected after incu-
bation in PBS for 24 hr at 37C (Figure 2C), and no MQ was
detected after boiling for 1 hr (data not shown). This supports
our hypothesis that decomposition of PRIMA-1 and PRIMA-1MET
is critical for their biological activity.
We isolated HPLC fractions corresponding to MQ (p15 min)
and the peak at 24 min that contains the unidentified products.
Concentrations of these products were determined based on
the decrease of the HPLC peak of the parent compound during
decomposition and on the relative yield of the products based on
the ultraviolet irradiation (UV) spectrometry. The obtained frac-
tions were concentrated under vacuum and tested in Saos-2
and Saos-2-His273 cells using the WST-1 assay. For MQ
(p15), we obtained IC50 values of 20.6 ± 0.4 mM in Saos-2 and
14.8 ± 3.9 mM in Saos-2-His273 cells. For p24, the IC50 values
were 14.8 ± 4.0 and 8.8 ± 0.1 mM, respectively. These fractions
were also assayed for induction of DNA fragmentation by fluo-
rescence-activated cell sorter propidium iodide (FACS-PI)
(Figure 2D). Thus, these results show that both major decompo-
sition products of PRIMA-1 havemutant p53-dependent activity.
Role of Thiol Modification for the Biological Effect
of PRIMA-1 and PRIMA-1MET
One of the decomposition products of PRIMA-1 and PRIMA-
1MET, MQ, has a chemically active double bond (Figure 2A)
that is prone to participate in reactions of nucleophilic addition.
In a cellular environment, protein thiol groups will be primary
targets for such reactions. To investigate whether covalent
modification of thiols plays a role for the observed biological
effects of PRIMA-1 and PRIMA-1MET, we pretreated H1299-
His175 cells with 5 mM N-acetylcysteine (NAC), followed by378 Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc.addition of PRIMA-1. NAC completely blocked PRIMA-1-
induced growth suppression and apoptosis (Figures 3A and
3B). NAC also blocked the effect of MIRA-3 (Bykov et al.,
2005a) and STIMA-1 (Zache et al., 2008), two substances that
suppress growth of human tumor cells in a mutant p53-depen-
dent manner similar to PRIMA-1. In contrast, NAC only partially
blocked the effect of the chemotherapeutic drugs vinblastin,
camptothecin, and paclitaxel (Figure 3A). Analysis by WST-1
and FACS-PI showed that NAC does not block wild-type p53-
induced apoptosis in the absence of PRIMA-1 in BL41-tsp53
and J3D-tsp53 cells upon activation of wild-type p53 expression
at 30C (data not shown). Incubation of NAC with PRIMA-1MET
overnight at 37C resulted in complete depletion of the parent
compound and the appearance of other products as shown by
HPLC (Figure 3C). MS analysis of the isolated fractions con-
firmed adduct formation between NAC and PRIMA-1MET via
substitution of a methoxy group andmainly by nucleophilic addi-
tion to a carbon-carbon double bond (Figure 3C). The reaction
between NAC and MQ is very rapid and is nearly complete in
1 min at 37C (data not shown).
Because glutathione is an important component of the cellular
redox control and xenobiotic neutralizing system, we speculated
that inhibition of glutathione synthesis by buthionine sulfoximide
(BSO) might potentiate the effect of PRIMA-1. Indeed, BSO
dramatically increased the growth suppression effect of PRIMA-1
in both H1299 and H1299-His175 cells. However, BSO itself did
not induce significant growth suppression in these cells. The
selectivity for mutant p53-expressing cells was retained (Fig-
ure 3D). Altogether, these results provide strong evidence that
modification of thiols is involved in the biological activity of
PRIMA-1 and PRIMA-1MET.
PRIMA-1MET Promotes an Oxidative Environment
in Tumor Cells
If PRIMA-1 and PRIMA-1MET exert their biological effects
through regulation of the redox status in tumor cells, for instance
by alkylating thiols, then treatment with PRIMA-1 or PRIMA-1MET
should induce an oxidative cellular milieu. To test this prediction,
we treated Saos-2 and Saos-2-His273 cells with PRIMA-1MET for
24 hr, stained cells with DCF, a reduced form of fluorescein that
fluoresces upon oxidation, and analyzed the cells by FACS (Bass
et al., 1983). This experiment revealed that PRIMA-1MET causes
increased oxidation in a mutant p53-dependent manner (Fig-
ure 3E). No oxidation was observed in p53 null cells even at
100 mM of PRIMA-1MET. Similar results were obtained with
parental p53 null H1299 cells and the mutant p53-expressing
H1299-His175 cells. Interestingly, cisplatin did not cause any
increased oxidation in Saos-2-His273 even at cytotoxic concen-
trations, although it induced reactive oxygen species (ROS) in
HCT116 colon carcinoma cells expressing wild-type p53 (data
not shown). These data suggest that PRIMA-1MET exerts its
effect in part via restoring ROS-inducing ability to mutant p53,
rather than indiscriminately alkylating thiol groups in proteins.
PRIMA-1 and PRIMA-1MET React Covalently
with Thiol Groups in Mutant p53
Because at least one degradation product of PRIMA-1 and
PRIMA-1MET possesses thiol-modifying activity, we tested
whether PRIMA-1 modifies thiol groups in proteins in vitro.
Cancer Cell
Mechanism of Mutant p53 Reactivation by PRIMA-1Figure 2. Active Chemical Groups in Mutant p53-Reactivating Compounds
(A) Conversion of PRIMA-1 and PRIMA-1MET. A reactive chemical group, i.e., a double bond coupled to an electron-withdrawing group forming a classical Michael
acceptor, is indicated in MQ, a common decomposition product of PRIMA-1 and PRIMA-1MET.
(B) Similar reactive groups are indicated in MIRA-3, CP-31398, and STIMA-1.
(C) Structural formula and HPLC profiles of untreated (left panel) and preheated (right panel) PRIMA-D. Preheating was performed in PBS for 24 hr at 37C.
(D) FACS-PI analysis demonstrating induction of mutant p53-dependent cell death in Saos-2 osteosarcoma cells by major decomposition products of PRIMA-1.
Data are shown as mean and standard error of the mean (±SEM).PRIMA-1 and PRIMA-1MET preincubated at 37C for 3 days
decreased the number of free thiols in bovine serum albumin
(BSA) in a concentration-dependent manner as determined by
the Ellman reagent (Ellman, 1959) (data not shown). To examinealkylation of thiols in mutant p53, we treated recombinant gluta-
thione S-transferase (GST) His175 or GST-Gln248 mutant p53
with PRIMA-1 or PRIMA-1MET that had been preincubated at
either 90C for 20 min or 37C for 3 days, and assessed thiolCancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc. 379
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Mechanism of Mutant p53 Reactivation by PRIMA-1Figure 3. The Biological Effect of PRIMA-1 Is Inhibited by NAC
(A) NAC completely blocks the cytotoxic effect of PRIMA-1, PRIMA-1MET, MIRA-3, and STIMA-1 in H1299-His175 cells, as shown by the WST-1 proliferation
assay, whereas only partial protection against vinblastin, camptothecin, and paclitaxel was observed. Data are shown as mean ± SEM.
(B) Treatment with NAC prevents PRIMA-1MET-induced cell death in H1299-His175 cells according to PI staining and FACS.
(C) Left panel shows reverse-phase HPLC profile of PRIMA-1MET incubated with NAC at 37C for 3 days in 50 mM Tris-HCL (pH 7.5). The new products a and
b were collected on HPLC and analyzed by MS. Right panel shows the identified structures of PRIMA-1MET-NAC adducts based on MS data.
(D) Glutathione depletion by BSO increases sensitivity of H1299 and H1299-His175 cells to PRIMA-1MET. Data are shown as mean ± SEM.
(E) PRIMA-1MET treatment induces ROS in Saos-2-His273 cells in a concentration-dependent manner as shown by DCF staining and FACS. Data are shown as
mean ± SEM.380 Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc.
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Figure 4. PRIMA-1 Decomposition Products Bind to p53 In Vitro and in Living Cells
(A) PRIMA-1, PRIMA-1MET,PRIMA-3, STIMA-1, andMIRA-3 reduce free thiols in recombinantGST-His175andGln248mutantp53.Dataareshownasmean±SEM.
(B) Treatment with preheated PRIMA-1 increases the molecular mass of the His175 mutant p53 core domain. The expected gain of molecular weight is 137 and
166 Da, depending on the type of modification.
(C) Analysis of [14C]-PRIMA-1 binding to recombinant GST-WT p53 showingmore efficient binding with increasing p53 unfolding. Data are shown asmean ± SEM.
(D) Quantification of radioactivity in p53 immunoprecipitates from extracts of cells treated with [14C]-PRIMA-1.
(E) Elution profile of immunoprecipitated mutant p53 from H1299-His175 cells on an mRP-C18 HPLC column. Western blot analysis demonstrated that the radio-
activity comigrated with cellular mutant p53.
(F) Analysis of radioactivity in p53 immunoprecipitates fromextracts of H1299-His175,H1299-WT, and J3D-tsp53 cells treatedwith [14C]-PRIMA-1.Data are shown
as mean ± SEM. Western blotting shows levels of immunoprecipitated p53 in representative samples.modification using biotinylated maleimide. PRIMA-1 and
PRIMA-1MET were used at concentrations that exceed the
concentration of the antioxidant DTT (10 mM) in the protein pre-parations. This analysis revealed that decomposition products of
PRIMA-1 and PRIMA-1MET can react covalently with thiols in
both mutant p53 proteins (Figure 4A). The structural analogCancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc. 381
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Mechanism of Mutant p53 Reactivation by PRIMA-1PRIMA-3 blocked thiols in mutant p53 with similar efficiency as
PRIMA-1 and PRIMA-1MET. As a positive control, we used the
mutant p53-targeting compounds MIRA-3 and STIMA-1, which
were even more efficient in blocking thiols in mutant p53
(Figure 4A).
To study binding of PRIMA-1 decomposition products to p53,
we performed MS analysis of recombinant wild-type and His175
mutant p53 core domains treated with PRIMA-1 preheated at
90C for 20 min. Again, we used PRIMA-1 at concentrations
that were high enough to override the reducing agent (TCEP) in
the p53 preparation. Treatment with 1 mM PRIMA-1 increased
the molecular weight of the mutant p53 core domain by 296
Da, corresponding to approximately 2 molecules of MQ (Fig-
ure 4B). Increasing concentrations of PRIMA-1 resulted in a
dose-dependent increase in the molecular weight of the p53
core up to 1395 and 1523 Da at 5 mM PRIMA-1. This corre-
sponds approximately to 10 molecules of MQ (Figure 4B).
Experiments with the wild-type p53 core domain yielded similar
results (data not shown). Based on our experiments with NAC,
we expect at least two PRIMA-1 and PRIMA-1MET adducts
with thiols: a dominant one produced by MQ that will result in
a 137Da gain ofmolecular weight, and another adduct that could
be produced via substitution of a hydroxyl group in PRIMA-1 or
amethoxy group in PRIMA-1MET, resulting in a 166Da increase in
molecular weight (Figure 3C). Also, formation of protein-formal-
dehyde adducts cannot be excluded. In order to examine the
relationship between p53 conformation and PRIMA-1 binding,
we incubated GST wild-type (WT) p53 at 37C for 30 min or at
90C for 5 min to induce increasing degrees of p53 unfolding,
as verified by enzyme-linked immunosorbent assay (ELISA)
using PAb1620 antibodies that recognize wild-type conforma-
tion of p53 (Figure 4C). Binding of [14C]-PRIMA-1 to GST-WT
p53 was proportional to the degree of p53 unfolding (Figure 4C).
To assess binding of PRIMA-1 decomposition products to
mutant p53 in living cells, we treated H1299-His175 and H1299
cells with [14C]-PRIMA-1 for 24 hr and immunoprecipitated
p53. We observed significant radioactivity in immunoprecipi-
tates with anti-p53 antibodies from the His175-expressing cells
as comparedwith the p53 null cells (Figure 4D). Next we fraction-
ated immunoprecipitated p53 on anmRP-C18 HPLC column and
assessed radioactivity in each fraction. The peak of radioactivity
at 12min comigrated with cellular His175mutant p53 protein ac-
cording to results of western blotting (Figure 4E). We conclude
that PRIMA-1 decomposition products also bind to mutant p53
in living cells.
We also investigated efficiency of [14C]-PRIMA-1 binding to
wild-type andHis175mutant p53 in living cells by immunoprecip-
itation of p53 from cell lysates and comparison of radioactivity in
the immunoprecipitateswith amount of p53 according towestern
blotting results. We did not detect any radioactivity by immuno-
precipitation in HCT116 WT p53+/+ cells, presumably due to
low levels of wild-type p53. To induce levels of wild-type p53,
we treated the cells with 1 mg/ml cisplatin 24 hr before adding
[14C]-PRIMA-1. We found that His175 mutant p53 binds about
twice as much [14C]-PRIMA-1 as wild-type p53 in cisplatin-
treated HCT116 wild-type p53+/+ cells (data not shown).
To allow an even more stringent comparison of binding in the
same cellular background, we used H1299 cells carrying either
exogenous wild-type or mutant p53. We treated the cells with382 Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc.100 mM [14C]-PRIMA-1 for 7 hr, immunoprecipitated p53, and
measured immunoprecipitated radioactivity by liquid scintillation
counting and amount of p53 in the immunoprecipitates by
western blotting. We detected almost 2-fold higher PRIMA-1
binding to His175mutant p53 than to wild-type p53 after normal-
izing to amount of immunoprecipitated p53 (Figure 4F). We per-
formed similar experiments in J3D-tsp53 cells that express
unfolded mutant p53 at 37C. Temperature shift to 32C induces
expression of wild-type p53 and apoptosis. Upon treatment with
[14C]-PRIMA-1 and immunoprecipitation with anti-p53 anti-
bodies, we detected a significant binding to mutant p53 (37C)
but only low levels of binding to wild-type p53 (32C) after
normalizing to amount of immunoprecipitated p53 (Figure 4F).
However, we cannot exclude that slower conversion at the lower
temperature (32C) could reduce the amount of generated
reactive product, which would underestimate binding to wild-
type p53.
Thus, our results with recombinant and cellular p53 show that
unfolded mutant p53 is modified by PRIMA-1 more efficiently
than the correctly folded wild-type protein.
PRIMA-1-Treated Recombinant Mutant p53 Triggers
Apoptosis in p53 Null Cells
To determine the role of alkylation of mutant p53 for the biolog-
ical effect of PRIMA-1, we treated recombinant mutant p53
proteins with PRIMA-1 prewarmed at 90C for 20 min, followed
by dialysis in order to remove unbound PRIMA-1. We then intro-
duced the treated protein directly into p53 null Saos-2 cells using
the Chariot protein transfer reagent. Mutant p53 transfer into
Saos-2 cells resulted in strong nuclear and cytoplasmic p53 im-
munostaining in a majority of the cells after 2 hr (Figure 5A). p53
remained in the cells 24 hr after protein transfer (data not shown).
Introduction of untreated GST-WT p53 reduced Saos-2 cell
survival by 28%, and PRIMA-1-treated wild-type p53 induced
cell death with significantly higher efficiency (Figure 5B).
PRIMA-1-treated GST-His175 and GST-Gln248 mutant p53
were equally efficient in inducing cell death upon Chariot trans-
fer, whereas PRIMA-1-treated BSA was entirely nontoxic
(Figure 5B). Importantly, transfer of GST-Gln248 mutant p53
treated with PRIMA-1 that had not been prewarmed failed to
induce cell death (data not shown). As expected, dialyzed pre-
warmed PRIMA-1 without protein had no effect on Saos-2 cells
(Figure 5B). Treatment of the cells with 5 mM NAC before and
during protein transfer provided only minor protection against
cell death induced by PRIMA-1-treated mutant p53 (data not
shown), confirming that PRIMA-1-modified mutant p53 rather
than soluble PRIMA-1 is responsible for the biological effect.
PRIMA-1-treated GST-Gln248 and GST-His175 mutant p53
induced expression of 14-3-3 protein in Saos-2 cells after 6 hr
according to immunostaining results (Figure 5C and data not
shown). At 24 hr, we observed a considerable increase in the
fraction of cells with G2/M DNA content and a substantial sub-
G1 cell population, indicating G2 cell cycle arrest and apoptosis
(Figure 5D).
Both PRIMA-1-treated recombinant mutant p53 proteins
induced expression of PUMA in Saos-2 cells after 6 hr (Fig-
ure 6A). Introduction of PRIMA-1-modifiedmutant p53:s induced
significant Bax protein expression after 6 hr in contrast to
untreated mutant p53 or dialyzed prewarmed PRIMA-1 alone
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Figure 5. PRIMA-1-Modified Mutant p53 Induces G2/M Arrest and Cell Death in p53 Null Cells
(A) p53 immunostaining of Saos-2 cells upon transfer of GST-His175 mutant p53 protein. Untreated Saos-2 cells were used as control. Scale bars = 100 mm.
(B) Cell survival as determined by counting viable cells after transfer of GST-WT p53, GST-His175, or GST-Gln248 mutant p53 or BSA treated either with PBS or
preheated PRIMA-1. Proteins were dialyzed before transfer to remove any unbound PRIMA-1. Data represent average number (mean ± SEM) of unfragmented
DAPI-stained cell nuclei from four vision fields (403) in three independent experiments. GST-WT p53 showed weak cytotoxicity in Saos-2 cells. Transfer of
PRIMA-1-treated GST-WT p53, GST-His175, and GST-Gln248 mutant p53 into Saos-2 cells induced substantial cell death, whereas PRIMA-1-treated BSA
had no effect.
(C) Induction of 14-3-3 protein by PRIMA-1-treated GST-His175. Scale bars, 100 mm.
(D) FACS analysis of Saos-2 cells after transfer of GST-Gln248mutant p53 protein treatedwith either PBS or preheated PRIMA-1 revealed that PRIMA-1-modified
recombinant mutant p53 induces DNA fragmentation and G2/M cell cycle arrest.(Figure 6B). As shown in Figure 6C, reverse-transcriptase poly-
merase chain reaction (RT-PCR) confirmed induction of Bax at
themRNA level. Introduction of GST-His175mutant p53 resulted
in a strong upregulation of NOXA and a somewhat weaker induc-
tion of PUMA and Bax mRNA after 2 hr according to RT-PCR
results. GST-WT p53 induced only Bax mRNA, but not as effi-
ciently as GST-His175 mutant p53 (Figure 6D). In agreement
with these results, we observed an 2-fold increase in the
capacity of GST-His175 mutant p53 to bind to a p53 consensus
DNA binding site after PRIMA-1 treatment, transfer into p53 null
cells, and analysis of total cell extracts by the TransAM assay
(data not shown). Interestingly, recombinant PRIMA-1-treated
GST-His175 mutant p53 protein alone did not show any
increased DNA binding as compared with mock-treated re-combinant GST-His175 mutant p53. This suggests that cellular
factors and/or additional modifications of p53 that are lacking
in bacteria are crucial for mutant p53 restoration by PRIMA-1.
Indeed, we observed that PRIMA-1-treated GST-His175 is
phosphorylated on Ser15 upon introduction into Saos-2 cells ac-
cording to immunostaining with an antibody specific for Ser15-
phosphorylated p53 (data not shown).
We detected a robust caspase activation at 24 hr (Figure 7A).
Consistent with our earlier findings, PRIMA-1-treated GST-
Gln248 mutant p53 generated ROS in Saos-2 cells (Figure 7B).
To extend our results to mutant p53 derived from human tumor
cells, we purified His175 mutant p53 from H1299-His175 cells
by size-exclusion chromatography, exposed it to preheated
PRIMA-1, and dialyzed and transferred the protein into p53Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc. 383
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Figure 6. PRIMA-1-Modified Mutant p53 Triggers Activation of Proapoptotic p53 Target Proteins Leading to Apoptosis in p53 Null Cells
(A) Induction of PUMA protein by PRIMA-1-treated GST-Gln248 mutant p53 as shown by immunofluorescence staining. Scale bars = 100 mm.
(B) Bax immunostaining of Saos-2 cells treated with 50 mM dialyzed preheated PRIMA-1, 2 mg GST-His175 mutant p53, or GST-His175 mutant p53 treated with
preheated PRIMA-1 demonstrates induction of Bax expression by preheated PRIMA-1-treated GST-His175 mutant p53 but not untreated GST-His175 mutant
p53 or preheated PRIMA-1 alone. Scale bars, 100 mm.
(C) GST-His175 mutant p53 treated with preheated PRIMA-1 induces Bax mRNA in Saos-2 cells as shown by RT-PCR. This effect is dependent on the amount of
mutant p53 protein. ++ and +++ indicate 5 and 10 mg protein, respectively. Data are shown as mean ± SEM.
(D) PRIMA-1-modifiedGST-His175mutant p53 upregulates NOXA, PUMA andBaxmRNA in Saos-2 cells, whereas PRIMA-1-modified GST-WT p53 only induces
Bax mRNA. Data are shown as mean ± SEM.H1299 cells. PI staining and FACS analysis showed that PRIMA-
1-treated His175 mutant p53 induced significant cell death in
a concentration-dependent manner at 24 hr (Figure 7C). There-
fore, modification of mutant p53 per se is sufficient for PRIMA-
1-induced tumor cell death.
DISCUSSION
Pharmacological reactivation of mutant p53 should trigger
massive cell death and efficiently eliminate tumors. This notion is
supported by studies demonstrating that restoration of functional
p53 in mouse tumors in vivo rapidly eliminates tumors through
apoptosis and/or senescence (Martins et al., 2006; Ventura et al.,
2007; Xue et al., 2007). Screening of chemical libraries has led to
the identification of small molecules that restore tumor suppressor
activity to mutant p53 (Bykov et al., 2002b, 2005a; Foster et al.,
1999), raising hopes for the development of novel efficient cancer384 Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc.therapy. However, the exact molecular mechanism(s) of mutant
p53 reactivation by such compounds remains unclear. It is not
known whether they actually interact physically with mutant p53.
Our previous studies showed that the ability of the maleimide-
derived molecule MIRA-1 to reactivate mutant p53 is linked to its
thiol-alkylating activity (Bykov et al., 2005a). Here we demon-
strate that PRIMA-1 is converted to reactive products that react
with nucleophiles and thus alkylate thiol groups in proteins. CP-
31398 harbors a reactive carbon-carbon double bond, raising
the possibility that it too can participate in such reactions (Fig-
ure 2B). Our finding that growth suppression induced by
PRIMA-1 and PRIMA-1MET was completely blocked by the thiol
group donor NAC strongly supports the idea that thiol modifica-
tion is important for their biological activity. We confirmed that
the PRIMA-1 and PRIMA-1MET decomposition product MQ, as
well as MIRA-1, CP-31398, and STIMA-1 (Zache et al., 2008),
form adducts with NAC via its free thiol group, indicating that
Cancer Cell
Mechanism of Mutant p53 Reactivation by PRIMA-1this reaction accounts for the observed NAC-mediated protec-
tion. In contrast, NAC provided only minor protection against
chemotherapeutic drugs that do not possess alkylating activity.
Thus, although the identified mutant p53-targeting compounds
appear structurally different at first glance, they share a common
chemical reactivity as Michael acceptors, suggesting a similar
molecular mechanism of action.
We confirmed covalent modification of the p53 core domain
in vitro by MQ and other decomposition products using MS.
Importantly, our immunoprecipitation experiments with radioac-
tively labeled PRIMA-1 indicated that covalent modification of
mutant p53 by MQ and/or other degradation products of
PRIMA-1 occurs in living cells. Although it is yet to be shown that
PRIMA-1 can modify mutant p53 in tumor cells also in vivo, such
modification is likely to occur based on our in vitro results and
data on in vivo decomposition and distribution of PRIMA-1. We
have previously shown that treatment of recombinant mutant
p53 with PRIMA-1 restores wild-type conformation (Bykov et al.,
2002b). Taken together, these results indicate that covalentmodi-
ficationofoneorseveral cysteine (Cys) residues in thecoredomain
is responsible for restoration of wild-type p53 conformation.
Our data do not allow any conclusions as to which of the 10
Cys residues in the p53 core domain that could be modified by
MQ and other PRIMA-1 decomposition products. However,
Cys182, Cys229, Cys242, and Cys277 are exposed on the
surface of the core and are thus potential targets for modification
(Cho et al., 1994; Sun et al., 2003). Additional cysteines are prob-
ably exposed in partially or completely unfolded p53 core
domains. Thus, mutant p53 might be more amenable to this
type of covalent modification than wild-type p53. Indeed, our
data show that unfolded p53 is more extensively modified by
PRIMA-1 than correctly folded recombinant p53. Similarly,
PRIMA-1 binds more efficiently to His175 mutant p53 than to
wild-type p53 in cells.
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Figure 7. PRIMA-1-Modified Mutant p53
Induces ROS and Triggers Apoptosis in p53
Null Cells
(A) FACS analysis showing that GST-Gln248
mutant p53 treated with preheated PRIMA-1 acti-
vates caspases in Saos-2 cells. This effect is
dependent on the amount of mutant p53. +, ++,
and +++ indicate 0.5, 1, and 2 mg protein, respec-
tively. Data are shown as mean ± SEM.
(B) GST-Gln248mutant p53 treated with preheated
PRIMA-1 induces ROS in Saos-2 cells as shown by
DCF staining.
(C) Purified His175 mutant p53 from H1299-His175
cells was treated with PBS or different concentra-
tions of preheated PRIMA-1 and transferred into
H1299 cells. FACS-PI analysis showed that trans-
fer of preheated PRIMA-1-treated cellular mutant
p53 induces significant cell death.
A key question is how alkylation of thiol
groups in mutant p53 could restore native
conformation to the core. First, formation
of inter- and intramolecular thiol-mediated
interactions such as disulfide bonds might
cause aggregation of mutant p53 and/or
lock the core domain in an unfolded conformation. Alkylation
might prevent the formation of such disulfide bonds and thus
potentially increase the fraction of the protein that is capable of
binding DNA and regulate target gene transcription. Second, the
formation of adducts in the core domain might create novel DNA
contacts, allowingmore efficient DNAbinding and hence transac-
tivation of p53 target genes. Third, PRIMA-1 adducts might pro-
mote correct folding of the core domain by creating additional
contacts with amino acids in the core via hydrogen bonding and/
orhydrophobic interactions.AnalysisofPRIMA-1-modifiedmutant
p53 byX-ray crystallography should ultimately provide information
about the structural consequences of cysteine alkylation.
It should alsobekept inmind that alkylationof thiolsmight regu-
late the activity of redox modulators of p53. Redox regulation of
p53 is supported by data from yeast studies in which lack of thio-
redoxin reductaseactivitywasshown to result in theaccumulation
of oxidized thioredoxin, leading to p53 oxidation and inactivation.
However, in a double yeast mutant deficient for both thioredoxin
reductase and thioredoxin, p53 was reduced and could fold into
a DNA-binding transcriptionally active conformation (Merwin
et al., 2002). In human cells, Ref-1/APE, a thioredoxin-regulated
protein implicated in DNA repair and thiol recycling, was shown
to participate in the control of p53 DNA binding (Jayaraman
et al., 1997; Seemann and Hainaut, 2005). Therefore, PRIMA-1
conversion products like MQ could act by modifying a cascade
of redox interactions that are critical for p53 folding, perhaps by
targeting and inhibiting electron transfer reactions between p53
and redox regulators such as Ref-1 or thioredoxin.
The redox mechanism suggested by our data is supported by
previous studies showing that the compound amifostine (North
et al., 2002) activates wild-type p53 by regulating its redox
status. WR-1065, the active form of amifostine, was shown to
bind directly to p53 (Shen et al., 2001), resulting in restoration of
transcription-transactivationactivity toMet272mutant p53 (NorthCancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc. 385
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that inhibit proliferation of cells expressing mutant p53 but not
wild-type p53-expressing cells yielded 3-methylene-2-norborna-
none, a compound that restores native conformation to mutant
p53 in cells similar to PRIMA-1 (Reddy et al., 2004). Of note,
amethylene group in 3-methylene-2-norbornanone is associated
with a keto-function that is a characteristic feature of Michael
acceptors, and this compound has striking structural similarities
to MQ, one of the decomposition products of PRIMA-1.
Introduction of PRIMA-1-treated GST-His175 or GST-Gln248
mutant p53 or cellular His175 mutant p53 in human tumor p53
null cells induced a characteristic ‘‘wild-type p53-like’’ biological
response. We observed induction of 14-3-3 protein followed by
G2/M cell cycle arrest, as well as induction of PUMA and Bax
before the onset of apoptosis according to caspase activation
and DNA fragmentation. PRIMA-1-treated mutant p53 showed
increased binding to a p53 consensus DNA motif. This is fully
consistent with the observed upregulation of the p53 transcrip-
tional targetsNOXA,PUMA,andBaxat themRNA level upon intro-
duction of PRIMA-1-modified mutant p53 into cells. Interestingly,
GST-WT p53 modified by PRIMA-1 was somewhat less active in
upregulation of p53 target genes at the time point analyzed,
possibly due to less efficient PRIMA-1 binding to wild-type p53.
We also observed that transfer of PRIMA-1-modified mutant p53
induced ROS, consistent with our findings of ROS induction in
PRIMA-1-treated mutant p53-expressing tumor cells. These
resultsare inagreementwithpreviousobservationsdemonstrating
that wild-type p53-dependent apoptosis involves induction of
ROS production (Johnson et al., 1996; Polyak et al., 1997; Sablina
et al., 2005), andstrongly support thenotion thatPRIMA-1 restores
wild-type function tomutant p53. Thus, our protein transfer experi-
ments demonstrate that modification of mutant p53 by PRIMA-1
decomposition products per se is sufficient to restore wild-type
activity tomutant p53 and induce apoptosis in human tumor cells.
Because PRIMA-1 is converted to products that can modify
thiol groups, PRIMA-1 treatment could potentially affect multiple
cellular targets. How does PRIMA-1 preferentially target mutant
p53-expressing tumor cells? First, alkylation of thiols might
depend on the particular structural environment at a given thiol
group andmight be restricted by steric hindrance. Thus, the total
number of cellular protein targets is probably limited and there
are presumably preferred targets. Second, it is conceivable
that thiol alkylation will have different consequences in different
proteins; for many proteins, suchmodification will be functionally
neutral or have relatively minor consequences, whereas thiol
modification of abundantly expressed mutant p53 will trigger
robust apoptosis. Our observation that PRIMA-1-treated mutant
p53 but not PRIMA-1-treated BSA is capable of triggering tumor
cell apoptosis supports this idea. The general notion of target-
selective thiol-modifying compounds is supported by studies
of follow-upmolecules to Iressa that target the epidermal growth
factor (EGF) receptor. Such compounds, e.g., HKI-272, are
Michael acceptors that bind covalently to a cysteine residue in
the receptor kinase domain (Kwak et al., 2005). Nonetheless,
extensive modification of thiols by PRIMA-1 conversion prod-
ucts might induce changes in the cellular milieu that result in
p53-independent cell death. Thismight account for the observed
cytotoxic effect of PRIMA-1 at high concentrations, even in
tumor cells carrying wild-type p53 or lacking p53.386 Cancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc.Our findings raise the question whether MQ could be used
directly as a mutant p53-targeting compound. However, MQ is
a reactive compoundwith limited stability at physiological condi-
tions. Administration of MQ might cause side effects due to
adduct formation in the extracellular environment. The delivery
of MQ in the form of a prodrug, i.e., PRIMA-1, allows more effi-
cient introduction in tumor cells where conversion will generate
the active substance. Furthermore, we cannot exclude a role
of other decomposition products in the mutant p53-dependent
effects of PRIMA-1.
We have demonstrated that PRIMA-1 is converted to
compounds that can modify thiol groups. Strikingly, several
other known mutant p53 targeting compounds, including WR-
1065, and MIRA-1, have been shown modify thiol groups and
affect the cellular redox state. This suggests a common mecha-
nism for mutant p53 reactivation among these compounds. We
believe that our identification of thiol modification as a mecha-
nism for mutant p53 reactivation by PRIMA-1 will facilitate the
design of even more potent mutant p53-selective compounds
and ultimately the development of truly efficient drugs for the
treatment of cancer.
EXPERIMENTAL PROCEDURES
Reagents, Antibodies, and Cells
Human Saos-2 osteosarcoma and H1299 lung adenocarcinoma cells are p53
null. The sublines Saos-2-His273 and H1299-His175 carry the indicated tetra-
cycline-regulated mutant p53-expression constructs (Tet-off), and H1299-WT
carries WT p53 expression construct (Tet-on). Human BL41-tsp53 Burkitt
lymphoma and mouse J3D-tsp53 T-lymphoma cells carry a mouse tempera-
ture-sensitive (ts) Val135 mutant p53 construct that is expressed as wild-
type p53 at 30C. Human HCT116 colon carcinoma cells carry wild-type
p53 (p53+/+), and the isogenic HCT116 (p53/) cells are p53 null. Polyclonal
rabbit anti-p53 and anti-Bax antibodies and monoclonal mouse PAB1620
and anti-p53Ser15 antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA), fluorescein isothiocyanate-conjugated and Texas-Red-conjugated
anti-rabbit immunoglobulin were from Vector Laboratories (Burlingame, CA).
Western blotting and ELISA with the PAb1620 antibody were performed
according to standard procedures. Chariot protein transfer reagent was
from Active Motif (Rixensart, Belgium). [14C]-PRIMA-1, labeled randomly at
C11 or C9 at one of the methylol groups, was from Amersham (Sweden). All
other reagents were of analytical grade and obtained from Sigma.
HPLC Analysis
HPLC was performed on a Beckman instrument operated with System Gold
and coupled to a 156 diode array detector module. A Kromasil C18 column
4.5 3 250 mm, 5 mm particle size (Phenomenex, Torrance, CA) was used.
The separation was performed at ambient temperature employing a gradient
elution in which water was mixed with methanol. The elution started with 7%
methanol immediately followed by a linear gradient for 35min up to 40%meth-
anol. Isocratic elution with 40% methanol continued for 5 min followed by
a linear gradient to 100% methanol in 5 min. The flow rate was 0.7 ml/min.
Products were detected by absorbance at 300 nm by a UV diode
array detector. For the experiments with radiolabeled PRIMA-1, fractions
were collected every 0.7 min and radioactivity was assessed by scintillation
counting.
For analysis of immunoprecipitated p53 from cells, amacroporousmRP-C18
column 4.6 3 50 mm (Agilent Technologies, Santa Clara, CA) was used. The
separation was performed at 45C by employing a gradient elution in which
solvent A (0.1% TFA in water) was mixed with solvent B (0.08% TFA in aceto-
nitril). The elution started with 3% B immediately followed by a linear gradient
for 2 min up to 10% B, then at 5 min up to 70% B in 5 min and at 10 min up
to 100% B in 2 min. The flow rate was 0.7 ml/min. Fractions were collected
every minute and radioactivity was assessed by scintillation counting.
Cancer Cell
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was used for size-exclusion chromatography. Separationwas performed using
isocratic elution with 50 mM NaH2PO4 (pH 6.7) at a flow rate of 0.9 ml/min.
Fractions were collected every 0.5 min and then analyzed for p53 content by
ELISA using a standard protocol.
Mass Spectrometry and NMR
Wild-type and mutant p53 (His175) in the context of thermostable t-p53 core
domain (residues 94–312) proteins were purified as described previously
(Joerger et al., 2005). Proteins were dialyzed into 25 mM sodium phosphate
(pH 7.2), 150 mM NaCl, and 1 mM TCEP. Then 1 M PRIMA-1 was heated in
the same buffer at 95C for 30 min. p53 at a concentration of 25 mMwas incu-
bated with 0 (control), 1, 2, 5, and 10 mM preheated PRIMA-1 for 2 hr at room
temperature (21C). Samples were diluted 10:1 into water to reduce ionic
strength and analyzed on a Voyager DE-PROMALDI-TOF mass spectrometer
(Applied Biosystems, UK). PRIMA-1 was used at concentrations that
exceeded the millimolar concentrations of the antioxidants TCEP and DTT in
the protein preparation. NMR studies were carried out on a 1H-NMR Varian
Gemini 400 MHz instrument.
Decomposition of [14C]-PRIMA-1 in Living Cells
H1299-His175 cells were plated in 24 well plates, 25,000 cells per well. Next-
day cells were treated with 50 mM [14C]-PRIMA-1. After 24 hr cells were har-
vested by trypsinization, and washed and lysed by five times freezing and
thawing in a buffer containing 400 mM NaCl, 10 mM HEPES (pH 7.9), 20%
glycerol, and 1 mM EDTA. Samples were cleaned from macromolecules
by precipitation in 90% ice-cold ethanol followed by centrifugation at
14,000 rpm for 20 min at 4C. The supernatant was dried in SpeedVac, redis-
solved in water, and fractionated by reverse-phase HPLC as described above.
Fractions were analyzed by liquid scintillation counting.
Decomposition and Distribution of [14C]-PRIMA-1 In Vivo
All animal studies were approved by the local ethical committee in Stockholm,
Sweden, and animal care was in accordance with institutional guidelines. Six
Balb/c mice were treated with 4.5 mg/kg [14C]-PRIMA-1 by a single intrave-
nous injection. Mice were divided into three groups, two animals in each.
The three groupswere killed 1, 4, or 24 hr after the injection. Serum and tissues
from brain, liver, lungs, kidneys, spleen, and muscle were collected from each
group. Additionally, in the third group, urine was collected during the 24 hr
period. Organ tissues were homogenized and radioactivity was measured by
liquid scintillation counting. Serum and urine were cleaned from macromole-
cules by precipitation in 90% ice-cold ethanol followed by centrifugation at
14,000 rpm for 20min at 4C. The supernatant was dried in a SpeedVac, redis-
solved in water, and fractionated by reverse-phase HPLC as described above.
Fractions were analyzed by liquid scintillation counting.
Binding of [14C]-PRIMA-1 to p53 in Living Cells
H1299 and H1299-His175 cells were plated at 15,000 cells/cm2, incubated
overnight, and treated with [14C]-PRIMA-1 (106 mCi/mmol) for 24 hr. Cells
were harvested and lysed 30 min on ice in 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 0.5% NP40, 2 mM PMSF, and 1% protease inhibitor cocktail. One
hundred and fifty micrograms of protein for each sample were precleared by
adding 10 ml Dynabeads protein A (Invitrogen, Sweden). Anti-p53 rabbit poly-
clonal antibody (2.5 mg) was added to each sample and incubated overnight at
4C. Immunoprecipitation was carried out by adding 10 ml beads to each
sample and incubating 1 hr on a rotating wheel at 4C. Beads were washed
three times in lysis buffer, and transferred to 10 ml scintillation liquid for count-
ing radioactivity in a Packard 2000CA Tri-Carb Liquid Scintillation Analyzer
(United Technologies Packard, CA). Alternatively, p53 was eluted from beads
with 0.1 M citric acid (pH 3.1), followed by western blotting and liquid scintilla-
tion counting as described above.
Binding of [14C]-PRIMA-1 to Recombinant GST-p53
Recombinant GST-WT p53 was incubated at different temperatures and
cooled on ice for 10 min. [14C]-PRIMA-1 was dissolved in 10 mM Tris-HCl
(pH7.5) and heated at 90C for 20min, cooled on ice for 15min, and then added
to the protein samples at final concentration of 10 mM. The samples were incu-
bated on ice for 20min. Reactions were stopped by incubation with 1mMNACfor 5 min on ice. p53 protein was precipitated with ice-cold ethanol by incuba-
tion for 15 min at 20C. Samples were centrifuged at 14,000 rpm at 4C for
15 min and the pellets washed twice with ethanol. Finally, samples were
dissolved in PBS by incubation at 40C for 30 min and transferred to the scin-
tillation vials, and radioactivity was measured by liquid scintillation counting.
Formaldehyde Release Assay
One hundred nanomoles of PRIMA-1 and PRIMA-1MET was diluted with PBS
and incubated at 37C for up to 3 days. The amount of formaldehyde was
assessed with the Purpald reagent as described elsewhere (Quesenberry
and Lee, 1996).
Protein Transfer
Recombinant GST-His175mutant p53 protein was purified from bacteria using
the Pierce protein extraction kit (Pierce, Rockford, IL). The protein was treated
for 2 hr at room temperature with either PBS or preheated PRIMA-1, dialyzed
against 33 800 ml PBS for 24 hr at 4C and transferred into Saos-2 cells with
the Chariot protein transfer reagent (Active Motif, Rixensart, Belgium) accord-
ing to the manufacturer’s protocol. His175 mutant p53 was purified from
H1299-His175 cells by SEC-HPLC, the collected fractions were analyzed by
ELISA for p53 content. Fractions contained p53were pooled. pHwas adjusted
to 7.5 and p53was treated either with PBS or with pre-warmed PRIMA-1. Then
samples were dialyzed against 33 800 ml PBS for 24 hr at 4C. The obtained
material was used for Chariot-mediated protein transfer into Saos-2 cells.
Determination of Free Thiol Groups
BSA or recombinant GST-His175 mutant p53 were treated with test
compounds or PBS on ELISA plates for 1 hr at RT, washed 3 times with
PBS and then incubated with 10 mM of maleimide-biotin conjugate (Pierce,
Rockford, IL). The wells were washed 3 times with PBS, blocked with 5%
skimmilk for 1 hr at RT, probed with avidine-HRP conjugate (Pierce, Rockford,
IL) diluted in 5% skimmilk for 30min, and washed 6 times with PBS. The signal
was developed with TMB HRP substrate (Pierce, Rockford, IL). Samples were
treated with HCl and absorbance wasmeasured at 490 nm in an ELISA reader.
Flow Cytometry
For DNA fragmentation assays, cells were grown on 24-well plates at an initial
density of 40000 cells/well, treated, fixed, stained with propidium iodide and
analyzed on a FACScan flow cytometer (Becton Dickinson, CA) according to
standard procedures. For caspase activation assay cells were labeled with
FLICA reagent (CaspaTag TM Pan Fluorescein Caspase activity kit, Intergen,
UK) according to the manufacturer’s instructions. Samples were analyzed
on a FACScan.
TransAM Assay
Cells were placed in six-well plates at a density of 200,000 cells per well, incu-
bated overnight, and then treated with recombinant protein. After 2 hr, cells
were harvested by trypsinization. Equal amount of total nuclear protein was
loaded on to a 96-well plate coated with an immobilized oligonucleotide con-
taining a p53 consensus binding site (TransAM, p53 Transcription Factor
Assay Kit, Active Motif, Belgium). Anti-p53 and anti-rabbit HRP were used to
quantify the amount of bound p53 protein. The HRP signal was developed
by a substrate provided by the manufacturer and samples were analyzed by
ELISA reader at 450 nm.
Real-Time PCR
Cells were treated with PRIMA-1 and harvested after 2 hr or 3.5 hr. RNA was
extracted using the RNeasy Mini Kit (QIAGEN, Sweden) according to the
manufacturer’s instructions. cDNA was synthesized according to standard
procedures and 100 ng cDNA was added to 10 ml 2x TaqMan Universal
PCR Master Mix (Applied Biosystems, CA) and 1 ml 20x TaqMan Gene
Expression Assay Hs00414514_m1 (Bax), Hs00560402_m1 (Noxa/PMAIP1),
Hs01080223_m1 (Puma/BBC3), or Hs99999905_m1 (GAPDH). Amplification
consisted of a first step with 2 min at 50C and 10 min at 95C followed by
40 cycles with 15 s denaturation at 95C and 1 min annealing/extension at
60C. Reactions were performed in 96-well optical PCR plates (Applied Bio-
systems, CA) using the ABI PRISM 7700 Sequence Detection System (AppliedCancer Cell 15, 376–388, May 5, 2009 ª2009 Elsevier Inc. 387
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Mechanism of Mutant p53 Reactivation by PRIMA-1Biosystems, CA). Results were analyzed with the comparative Ct method
using GAPDH as the endogenous control.
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